Retatrutide vs Survodutide
Side-by-Side Comparison
| Attribute | Retatrutide | Survodutide |
|---|---|---|
| Category | Metabolic / Triple Agonist | Metabolic / Dual Agonist |
| Mechanism | Retatrutide simultaneously activates three receptors: GLP-1 (reduces appetite, slows gastric emptying, improves insulin secretion), GIP (enhances insulin sensitivity, glucose control), and glucagon... | Survodutide simultaneously activates glucagon receptors (increasing hepatic fat oxidation, energy expenditure, and thermogenesis) and GLP-1 receptors (reducing appetite, slowing gastric emptying,... |
| Evidence Rating | B — Phase III / NDA Filed | B — Phase III / NDA Filed |
| Clinical Status | Phase 3 clinical trials (Eli Lilly TRIUMPH program) | Phase 3 clinical trials for MASH and obesity (Boehringer Ingelheim) |
| Safety Profile | GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate; GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) | GI adverse events (nausea, vomiting, diarrhea) similar to other incretin-based therapies; Heart rate increases observed (class effect) |
| Route | Subcutaneous (clinical trial formulation only) | Subcutaneous |
| Dose Range | Phase 2 tested 1, 4, 8, 12 mg weekly SC; optimal dose being determined in Phase 3 | Phase 2 tested 0.3-6.0 mg weekly; optimal dose being determined in Phase 3 |
| Frequency | Once weekly | Once weekly |
| Molecular Weight | N/A | N/A |
| Half-Life | ~6 days (allows once-weekly dosing) | ~5-6 days (allows once-weekly dosing) |
Overview
Retatrutide and Survodutide are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Retatrutide — Mechanism & Evidence
Retatrutide is a first-in-class investigational triple hormone receptor agonist (GIP, GLP-1, and glucagon) developed by Eli Lilly. In the Phase 2 trial (Jastreboff et al., NEJM 2023, n=338), the 12 mg dose achieved 24.2% mean body weight reduction at 48 weeks, with 100% of participants achieving at least 5% weight loss. Multiple Phase 3 TRIUMPH trials are ongoing, with TRIUMPH-4 (Dec 2025) reporting average loss up to 71.2 lbs with osteoarthritis pain relief. Expected FDA approval is 2027-2028.
Key claims: Unprecedented weight loss in Phase 2; Phase 3 confirms efficacy with osteoarthritis benefit; Improves glycemic control in type 2 diabetes.
Survodutide — Mechanism & Evidence
Survodutide is an investigational dual glucagon/GLP-1 receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Unlike tirzepatide (GIP/GLP-1), survodutide combines glucagon and GLP-1 agonism, adding glucagon-driven hepatic fat oxidation and energy expenditure to GLP-1-mediated appetite suppression. It has shown particular promise for MASH (metabolic dysfunction-associated steatohepatitis), achieving MASH resolution in 83% of patients at the highest dose in Phase 2, and is in Phase 3 trials for both obesity and MASH.
Key claims: High rates of MASH resolution; Significant weight loss; Liver fat reduction.
Shared Research Applications
Both peptides are studied for: Weight Management, Metabolic Health.
Retatrutide is also researched for: no additional unique applications.
Survodutide is also researched for: no additional unique applications.
Safety Considerations
Retatrutide: GI side effects (dose-related, 13-63% across dose groups): nausea, vomiting, diarrhea, constipation; mostly mild to moderate GI events partially mitigated with lower starting dose (2 mg vs 4 mg initial dose) Dose-dependent heart rate increases peaking at 24 weeks, declining thereafter
Survodutide: GI adverse events (nausea, vomiting, diarrhea) similar to other incretin-based therapies Heart rate increases observed (class effect) Dose-dependent tolerability — titration essential
Related Products
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Related Research News
Retatrutide Clinical Trial Results: Phase III TRIUMPH Data Shows Significant Weight Loss
Early reports from the Phase III TRIUMPH-1 trial suggest retatrutide, a novel triple agonist, has delivered substantial weight loss outcomes. These retatrutide clinical trial results indicate a potential shift in obesity treatment research, though full data analysis is pending.
Retatrutide Phase III TRIUMPH-1 Results: Unprecedented Weight Loss Reported at ADA26
Early reports from the American Diabetes Association 2026 meeting suggest retatrutide delivered unprecedented weight loss in the Phase III TRIUMPH-1 trial. Researchers and industry professionals are closely watching these retatrutide clinical trial results for implications in obesity and metabolic disease treatment.
Survodutide Shows Renal and Metabolic Gains in DKD Mouse Model at ECO 2026
Researchers presented data at the European Congress on Obesity (ECO) on survodutide's effects in a mouse model of advanced diabetic kidney disease (DKD). The drug improved kidney injury markers like albuminuria and glomerulosclerosis, along with metabolic measures such as body weight and glucose levels. These results suggest potential for broader applications if confirmed in human studies.